Bisphosphonates May Be Useful as Palliative Measure in Selected Patients
the ONA take:
Bisphosphonates may improve symptoms of hypercalcemia and prolong survival in patients with malignancy-associated hypercalcemia receiving palliative care, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
Because hypercalcemia can be a potentially fatal paraneoplastic complication of malignancy, researchers sought to determine the reversibility of hypercalcemia amongst patients not receiving treatment for their underlying malignancy and assess whether calcium correction improves symptoms.
For the study, researchers analyzed data from 63 patients with evidence of malignancy-associated hypercalcemia being treated with bisphosphonates. Results showed that 36 of the 63 participants achieved normal calcium levels following treatment with an intravenous bisphosphonate.
Researchers found that history of hypercalcemia in the past, age, and albumin levels impacted whether patients achieved a complete response. The study also demonstrated that a reduction in calcium level was associated with significantly improved survival and symptoms regardless of whether patients achieved normal calcium levels.
Malignancy-associated hypercalcemia typically manifests during the advanced phase of cancer, when the life expectancy of patients ranges from weeks to months.
Although bisphosphonates are the mainstay of treatment for this complication, they are not typically used in a palliative population.
Bisphosphonates may improve symptoms of hypercalcemia and prolong survival in patients receiving palliative care.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|